Untargeted metabolomics in the discovery of novel biomarkers and therapeutic targets for atherosclerotic cardiovascular diseases.
Authors: Dang VT, Huang A, Werstuck GH Abstract Cardiovascular disease (CVD) is the leading cause of mortality and morbidity worldwide. Four out of five CVD deaths are due to myocardial infarction or stroke. Despite many initiatives that have been established for CVD prevention and risk management, and new therapies to treat existing CVD, patients continue to die from cardiac events. Clearly, we need to identify new therapeutic targets and strategies. Early diagnosis of CVDs and identification of patients at high risk of developing adverse events would allow for timely intervention that prevents serious consequence...
Source: Cardiovascular and Hematological Disorders Drug Targets - April 24, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients.
CONCLUSION: SOCS1 promoter methylation level is not suitable to be used as one of the biomarker for predicting the possibility of acquiring resistance among CML patients treated with IM. PMID: 29669505 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - April 22, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Mutations and Common Polymorphisms in ADAMTS13 and vWF Genes Responsible for Increasing Risk of Thrombosis.
CONCLUSION: The increased or decreased activity of these two genes as a result of genetic changes and the development of thrombosis are a challenging and contradictory matter, and the study of genetic variability in ADAMTS13 and vWF genes may be helpful in the diagnosis of thrombotic disorders. PMID: 29669506 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - April 22, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Buxus sempervirens L. improves lipid profile in diabetic rats.
In conclusion, Buxus sempervirens leaf extract may be helpful in controlling the development of hyperlipidemia as well as atherosclerosis in diabetic animals. PMID: 29669507 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - April 22, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Sodium-glucose cotransporter 2 inhibitors: the impact on development and progression of heart failure.
CONCLUSION: The pleiotropic effects of SGLT-2 inhibitors seem to be translated in significant improvement of HF-related outcomes. On-going trials will provide further information on the impact of these agents in various high- and low-risk populations. PMID: 29618313 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - April 7, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Adenosine and adenosine 5'-triphosphate catabolism in systemic blood as a potential biomarker for doxorubicin cardiotoxicity in an experimental rat model in vivo.
Authors: Yeung PK, Purcell C, Akhoundi F, Agu RU Abstract BACKGROUND: Previous studies have shown that metabolism of adenosine 5'-triphosphate (ATP) in systemic blood is a potential surrogate biomarker for cardiovascular toxicity. OBJECTIVE: To investigate the acute effect of high dose of doxorubicin (DOX) on adenosine and ATP catabolism in systemic blood in vivo. METHOD: Sprague Dawley (SD) rats were each given either 10 mg/kg of DOX (n = 8) or normal saline (1 mL/kg, n = 11) twice daily for 4 doses by subcutaneous (sc) injection. Blood samples were collected sequentially for up to 6 hours for measuring ci...
Source: Cardiovascular and Hematological Disorders Drug Targets - April 7, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Platelet Activation Polymorphisms in Ischemia.
Authors: Saki N, Haybar H, Khodadi E, Zibara K Abstract Ischemia is a multifactorial disorder in which several genetic and environmental factors are involved. Platelets are the major causative agents of this disease because their elevated activity and aggregation would increase the risk of atherosclerosis and thrombosis, as well as ischemia. A number of polymorphisms in platelet receptors can increase the risk of ischemia and single-nucleotide polymorphisms (SNPs) have been detected in platelets. In addition, polymorphisms in other genes have been shown to cause platelet adhesion and aggregation that plays a role i...
Source: Cardiovascular and Hematological Disorders Drug Targets - March 28, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Regulation of Smooth Muscle Myosin Light Chain Phosphatase by Multi-site Phosphorylation of the Myosin Targeting Subunit, MYPT1.
Authors: Walsh MP, MacDonald JA Abstract Smooth muscle contraction is triggered primarily by activation of Ca2+/calmodulin-dependent myosin light chain kinase leading to phosphorylation of the regulatory light chains of myosin II. Numerous contractile stimuli also induce inhibition of myosin light chain phosphatase thereby prolonging the contractile response. The phosphatase is a trimeric enzyme containing a catalytic subunit, a regulatory, myosin-binding subunit (MYPT1) and a third subunit of uncertain function. MYPT1 is phosphorylated at multiple sites by several kinases, which regulate phosphatase activity, prot...
Source: Cardiovascular and Hematological Disorders Drug Targets - March 28, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

A rare case of tricuspid valve endocarditis caused by Enterococcus Gallinarum in a patient with recurrent urinary tract infection.
We present a case of an 85 years old male with history of valvular disease and permanent pace maker with past medical history of repetitive urinary tract infections in the previous months, who presented to the emergency department with fever, urinary disturbances, general malaise and positive blood cultures for Enterococcus Gallinarum. Echocardiography was a useful diagnostic method in the present case, showing the vegetation on the tricuspid valve. This case is notable because tricuspid valve endocarditis due to Enterococcus Gallinarum is a rare clinical condition and improves knowledge of disease and management in patien...
Source: Cardiovascular and Hematological Disorders Drug Targets - March 8, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Cholesterol Homeostasis and Liver X Receptor (LXR) in Atherosclerosis.
Authors: Guo S, Li L, Yin H Abstract Cholesterol is an important lipid for maintaining cellular membrane fluidity and generation of various hormones and bile acids. Thus it is critical to maintain cholesterol homeostasis including absorption, trafficking, biosynthesis, and efflux; dysregulation of cholesterol homeostasis may lead to human disorders such as atherosclerosis. As a cholesterol sensor, nuclear receptor liver X receptor (LXR) is an important factor regulating cholesterol homeostasis. Extensive research has been carried out to examine the roles of LXR in atherosclerosis. In this review, we summarize our c...
Source: Cardiovascular and Hematological Disorders Drug Targets - March 8, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Sodium-glucose cotransporter 2 inhibitors: potential cardiovascular and mortality benefits.
CONCLUSION: The initial data of SGLT-2 inhibitors suggest beneficial effects on cardiovascular risk among patients with diabetes mellitus. Several mechanisms are hypothesized to mediate the abovementioned benefits. Future randomized, controlled studies are need in order to unveil the contribution of each mechanism to these outcomes. PMID: 29485012 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - March 1, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Glucose lowering activity of Anvillea radiata Coss & Durieu in diabetic rats.
Glucose lowering activity of Anvillea radiata Coss & Durieu in diabetic rats. Cardiovasc Hematol Disord Drug Targets. 2018 Feb 22;: Authors: Eddouks M, Hebi M Abstract INTRODUCTION: Anvillea radiata Coss. &Durieu (Asteraceae) is an endemic plant from North Africa (Morocco and Algeria).This plant has many traditional uses including treatment of obesity and diabetes. AIM OF THE STUDY: the study aims to evaluate the antidiabetic effect of aqueous extract of Anvillea radiata (A. radiata) leaves on both normal and streptozotocin (STZ)-induced diabetic rats treated at a dose of 10 mg/kg body weig...
Source: Cardiovascular and Hematological Disorders Drug Targets - February 25, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Immunomodulatory and Anti-inflammatory Effects of Thymoquinone.
This study also found that TQ improves the imidacloprid toxicity through reducing oxidative stress and increasing chemokinesis, chemotaxis, phagocytic activity, antibody levels and the hemagglutination of immunoglobulins as well as by reducing serum MDA levels and hepatic enzymes. PMID: 29437018 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - February 15, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

What genetic tell us about cardiovascular disease in diabetic patients.
CONCLUSION: Predictive polymorphisms are risk estimators for CVD incidence in diabetes patients. . SNPs such as 894G>T in NOS3 gene, V16 in MnSOD gene, Rs3918188 in NOS3 gene and Rs11614913 in MiR-196a2 increase the risk of CVD in diabetic patients are precious polymorphisms for CVD prediction in diabetic population. CDKN2B, MTHFR and ACE genes have polymorphisms which increase the risk of diabetes and other polymorphisms on these genes increase the risk of CVD, we suggest these genes are valuable to study and find out if there are any polymorphisms that predict CVD susceptibility in diabetic patients. PMID: 2943701...
Source: Cardiovascular and Hematological Disorders Drug Targets - February 15, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Berberine encapsulated PLGA-PEG nanoparticles modulates PCSK-9 in HepG2 cells.
CONCLUSION: Nanotechnology drug delivery approach of Berberine modulates PCSK-9 in HepG2 cells, this approach may result in improving the drug pharmacokinetic performance and the intended target outcome. Further studies in animal models are needed to validate this result and explore the potential mechanistic components and function. PMID: 29422010 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - February 11, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Sodium-glucose cotransporter 2 inhibitors and ischemic stroke.
CONCLUSION: Despite the multiple pleiotropic effects of SGLT-2 inhibitors, these agents do not appear to affect stroke risk. Ongoing large trials with longer follow-up will evaluate whether the pleiotropic effects of this class will translate into benefits in ischemic stroke prevention. PMID: 29412119 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Sodium-glucose cotransporter 2 inhibitors and the risk of diabetic ketoacidosis; from pathophysiology to clinical practice.
CONCLUSION: SGLT-2 inhibitors certainly predispose to euDKA, but it is unclear if, as certain precipitating factors are usually recognized on the background, DKA would also occur in the absence of an SGLT-2 inhibitor. Further investigation is required in order to establish or not SGLT-2 inhibitors as causative factors of euDKA. PMID: 29412120 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Sodium-glucose cotransporter 2 inhibitors: impact on body weight and blood pressure compared with other antidiabetic drugs.
Authors: Imprialos K, Stavropoulos K, Stavropoulos N, Patoulias D, Petidis K, Grassos C, Dimitriadis K, Tsioufis C Abstract BACKGROUND: Sodium-glucose co-transporters 2 inhibitors have emerged as a novel antidiabetic class of drugs offering significant ameliorating effects on a variety of cardiovascular risk factors, secondary to their mechanism of action, including blood pressure and body weight. OBJECTIVE: The purpose of this article is to discuss available data on the impact of SGLT-2 inhibitors on blood pressure and body weight compared with other available antidiabetic drugs and to present potential mechan...
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Sodium-glucose cotransporter 2 inhibitors: nephroprotective impact on diabetic kidney disease.
CONCLUSION: The initial data suggest clinically meaningful benefits of the SGLT-2 inhibitors in diabetic patients in relevance with chronic kidney disease. Future, well-designed randomised clinical trials need to be further investigate such nephroprotective outcomes, that if confirmed could lead to new perspectives in the management of diabetic nephropathy. PMID: 29412122 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Sodium-glucose cotransporter 2 inhibitors: The pleiotropic mechanisms of actions.
CONCLUSION: The underlying mechanisms responsible for the SGLT-2 inhibitor actions, are pleiotropic and occur in the kidneys, as well as in other target organs. The comprehension of these mechanisms, not only permits us to understand their actions better, but it could also help us to predict more of their undisclosed favorable actions, as well as their rare adverse effects. PMID: 29412123 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Sodium-glucoser cotransporter 2 inhibitors: glucose lowering against other hypoglycemic agents.
CONCLUSIONS: SGLT-2i are a reliable second line therapy of T2DM, as they can be combined safely with metformin, sulfonylures, incretin mimetics, insulin as well as in triple combinations. In many studies they were prioritised as monotherapy with satisfying effect regarding HbA1c and FPG level reductions. PMID: 29412124 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.
Authors: Hebi M, Thewke DP Abstract Decades of research has provided evidence for the role of the endocannabinoid system in human health and disease. This versatile system, consisting of two receptors (CB1 and CB2), their endogenous ligands (endocannabinoids), and metabolic enzymes has been implicated in a wide variety of disease states, ranging from neurological disorders to cancer. CB2 has gained much interest for its beneficial immunomodulatory role that can be obtained without eliciting psychotropic effects through CB1. Recent studies have shed light on a protective role of CB2 in cardiovascular disease, an ail...
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Previous use of statins and atrial electrical remodeling in patients with cryptogenic stroke.
CONCLUSIONS: Our results show lower PWD values in cryptogenic stroke patients previously treated with statins. These findings provide support to the hypothesis that statins may play a role in modulating atrial electrophysiological and structural properties, preventing the occurrence of a slowed and heterogeneous atrial conduction and finally, reducing the occurrence of AF. PMID: 29332603 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - January 17, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Exosomes in Cholesterol Metabolism and Atherosclerosis.
CONCLUSION: This review will describe the current state of our knowledge of exosome involvement in the development of atherosclerosis. The transfer of signaling molecules, lipids, mRNAs, and microRNAs via exosomes with effects on monocyte and macrophage cholesterol metabolism, endothelial cell and platelet activation and smooth muscle proliferation will be discussed. Finally, therapeutic potential of exosomes and clinical application will be explored. PMID: 29299993 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - January 6, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Platelets structure, function and modulator capacity in replacement therapy.
CONCLUSION: Here we review the structure and function of platelets and discuss the mechanisms of alloimmunization to platelet transfusion. PMID: 29283062 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - December 30, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
CONCLUSION: JAK2 mutation is observed in patients with thrombosis, ischemia and other cardiovascular complications having abnormal increase in cell count even without definite clinical diagnosis of MPN. Therefore, identification of this mutation in these patients contributes to definite diagnosis of cardiovascular events. Also, cardiovascular complications in MPN patients can be prevented by targeting the factors involved in JAK/STAT signaling pathway. PMID: 29086702 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - November 1, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

A Review of the Current Role of Blood Clotting Analyzers in Clinical Practice.
CONCLUSION: This review provides a summary of clinical trials utilizing VETs in the aforementioned clinical scenarios, and suggests that VETs have demonstrated a capability to identify coagulopathies, utility in guiding algorithms to reduce the amount of transfusions, and a limited ability to predict bleeding events or mortality. PMID: 29086703 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - November 1, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

An overview on cardiovascular protective effects of catechins.
Conclusion: The current review has evaluated various studies on the role of catechins in the prevention and treatment of cardiovascular disorders by focusing on oxidative stress and inflammatory responses. PMID: 28933274 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - September 22, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Factors Associated with Pulmonary Embolism Recurrence and the Benefits of Long-term Anticoagulant Therapy.
CONCLUSION: Pulmonary embolism has a high recurrence rate. Permanent anticoagulant therapy should be considered for patients with idiopathic pulmonary embolism, a high thrombotic burden, and persistently elevated D-dimer levels during treatment, and for patients where therapy was initially delayed. PMID: 28925904 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - September 21, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Nanomedicine in the diagnosis and treatment of atherosclerosis - A systematic review.
Authors: Vaidyanathan K, Gopalakrishnan S Abstract BACKGROUND: Atherosclerosis is a chronic inflammatory condition causing very high morbidity and mortality. It is characterized by accumulation of plaques within arteries. Nanomedicine is an emerging field of medicine utilizing nanotechnology for advanced imaging and therapy. Nanomedicine has led to significant developments in the field of cardiovascular diseases, including atherosclerosis. Many nanoformulations have been developed with anti-atherosclerotic effects. Nanomedicine tools have been used in the imaging of atherosclerosis. Various nanocarriers have been e...
Source: Cardiovascular and Hematological Disorders Drug Targets - September 21, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Buxus sempervirens L improves streptozotocin-induced diabetes mellitus in rats.
CONCLUSION: According to all these findings, we conclude that AELBS at a low dose demonstrated a potent antihyperglycemic effect in streptozotocin rats and further investigations should be necessary of supporting the use of this plant in the management of diabetes by the Moroccan population. PMID: 28925906 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - September 21, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Atrial Fibrillation Ablation Increases Inflammation - Chemokine Modulation Suppresses Activation of Leukocytes Isolated after Ablation.
CONCLUSIONS: Patients undergoing AF ablation have significantly increased inflammatory markers. Inhibition of chemokine signaling, but not serine proteases, reduced activation of monocytes isolated from patients, in vitro. Targeting chemokines has potential for reducing post-ablation activation of circulating leukocytes. PMID: 28925907 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - September 21, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Fibrinolytic and Anticoagulation Therapy in Patients Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis for Pulmonary Embolism.
CONCLUSIONS: In patients with acute PE, our institution utilized low levels of anticoagulation during fibrinolytic administration and therapeutic doses after completion of fibrinolytic infusion. Standardized protocols for anticoagulation during UA-CDT are warranted. PMID: 28891451 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - September 12, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Congenital FX deficiency Rio Tercero: a new heterozygous missense mutation (Cys241Gly) with a potentiating effect by a polymorphism (c. 503-57C > T).
CONCLUSIONS: The polymorphism present in the family seems to be capable of potentiating the defect induced by the new mutation. This, safe for epigenetics phenomena, is the only possible explanation for the discrepancy found in the FX level between mother and daughter despite of the fact that both carried the same new mutation. PMID: 28891452 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - September 12, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Management of Hemophilic Arthropathy of the Ankle.
CONCLUSION: The ideal treatment for the hemophilic ankle when hematologic prophylaxis fails includes physiotherapy, orthoses, radiosynovectomy, arthroscopic ankle debridement (in the initial stages of cartilage degeneration), and ankle distraction, ankle fusion or total ankle replacement (in advanced stages of cartilage degeneration). PMID: 28891453 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - September 12, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Preface.
PREFACE. Cardiovasc Hematol Disord Drug Targets. 2017;17(1):2 Authors: Shen G PMID: 28786353 [PubMed - in process] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - August 9, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists.
Authors: Bhandare RR Abstract The serotonin 2B receptor subtype (5-HT2BR), located in central nervous system (CNS), cardiovascular system (CVS) and the gastrointestinal tract (GIT), is an important target for the treatment of migraine, obesity and irritable bowel syndrome. 5-HT2BR is necessary for the myocardial cell proliferation and differentiation at the embroyonic stage for healthy development of heart. Recently, its involvement in drug induced valvulopathy and other myocardial disorders have paved a way for selective antagonist for the treatment of cardiac disorders. The current review summarizes the limited p...
Source: Cardiovascular and Hematological Disorders Drug Targets - July 7, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Heart failure with preserved ejection fraction: A dilemma in treatment options.
Authors: Bramblett T, Teleb M, Albaghdadi A, Agrawal H, Mukherjee D Abstract Heart failure with preserved ejection fraction (HFpEF) makes up half of diagnosed heart failure cases and has similar outcomes compared to heart failure with reduced ejection fraction (HFrEF) but a discrepancy in knowledge and approach to treatment. HFpEF is diagnosed using the following criteria: symptoms, preserved ejection fraction (greater than 50%), and evidence of abnormal left ventricular filling or relaxation, or diastolic distensibility or stiffness. Studies conducted to examine the efficacy of angiotensin receptor blockers (irbes...
Source: Cardiovascular and Hematological Disorders Drug Targets - July 7, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

The intriguing occurrence of Segmental Arterial Mediolysis; Case report and concise literature review.
Authors: Chaudhry MA Abstract Segmental medial arteriolysis (SAM) is a unique arteriopathy highlighted by significant lytic changes in the medial wall of the blood vessels and can present from vague gastrointestinal discomfort to catastrophic abdominal bleeding and shock. We hereby present a concise review of this rare phenomenon with historic perspectives, epidemiology, and current concepts of etiology, pathogenesis, relevant clinical associations, treatment modalities, prognosis and future directions in SAM. In addition we present an interesting occurrence of this intriguing phenomenon in a forty-eight year old l...
Source: Cardiovascular and Hematological Disorders Drug Targets - July 7, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Anticoagulation in Tuberculosis patients not achieving a therapeutic range with Vitamin K antagonists: A Systematic Review.
Conclusion No published data were found that assessed the effect of NOA administered in combination with anti TB antimicrobials. Actually, Low Molecular Weight Heparin (LMWH) for VTE associated with TB should be considered a viable treatment option. Future studies are needed to establish the safety of NOA in this clinical scenari. PMID: 28676032 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - July 7, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Targeting the role of lipoprotein (a) in stroke.
Authors: Garelnabi M, Mazhar Z, Hughes A Abstract Stroke is the third leading cause of death in the United States, behind only heart disease and cancer, with over 140,000 associated deaths per year. Considerable research is ongoing to examine the role of modifiable risk factors which may cause or contribute to a stroke occurring. Although age and family history are generally considered to be major risk factors, there are several modifiable and non-modifiable risk factors that are linked to the pathogenesis of a stroke. Lipoprotein (a), or Lp(a), is a type of low-density lipoprotein containing an integral apoB100 co...
Source: Cardiovascular and Hematological Disorders Drug Targets - April 22, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Alcohol induced hepato cardiotoxicity and oxidative damage in rats: The protective effect of n-butanol extract of green tea (Camellia sinensis (L.) Kuntze).
CONCLUSION: These results suggest that n-butanol extract of Camellia sinensis protected the heart and the liver from binge ethanol induced injury through attenuating oxidative stress. PMID: 28294073 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - March 18, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Comparison of the acute hematopoietic capacities of erythropoietin and U-74389G concerning hematocrit levels.
CONCLUSIONS: The anti-oxidant capacities of U-74389G provide satisfactory acute hematopoietic properties; presenting approximately 12.66-fold hematocrit level rise than epo (p-value=0.0000). PMID: 28155601 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - February 6, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Epicardial Adipose Tissue: Another Tassel in the Complex Fabric of Atherosclerosis.
Authors: Alexopoulos N, Raggi P Abstract Atherosclerosis affects the majority of adult individuals in industrialized nations and it is beginning to affect even traditionally spared populations. The classic view has been that the precipitating events are intraluminal. However, good evidence supports the possibility that at least part of the atherosclerosis burden may be the consequence of extra-luminal noxious stimuli. Additionally, the epidemic of obesity, insulin resistance and diabetes mellitus has generated a strong interest in the potential role of visceral adipose tissue as an extra-luminal promoter of atheros...
Source: Cardiovascular and Hematological Disorders Drug Targets - January 27, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Biomarker assays for personalised stroke risk assessment in atrial fibrillation.
Authors: Hall A, Simpson RF, Mitchell AR Abstract Atrial fibrillation is a well-known independent risk factor for stroke yet there is no international consensus on guidelines regarding the introduction of anticoagulation in patients deemed at intermediate risk (e.g. CHA₂DS₂-VASc of 1). The evolution of cardiac biomarkers such as highly sensitive troponins and B-type natriuretic peptide as well as data on D-dimers, may offer incremental enhancements for personalised thromboembolism risk assessment. These markers provide prognostic data for risk of cardiovascular morbidities associated with atrial fibrillation an...
Source: Cardiovascular and Hematological Disorders Drug Targets - January 7, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

The sdLDL reduces MRC1 expression level and secretion of histamine in differentiated M2-macrophages from patients with coronary artery stenosis.
Authors: Yarnazari A, Najafi M, Hassanpour P, Hosseini-Fard SR, Amirfarhangi A Abstract The macrophage polarization is proposed to be involved in initial events and remodeling of atherosclerosis plaques. Mannose receptor, C type 1 (MRC1) is a trans-membrane glycoprotein participating in phagocytosis and, is highly expressed in the M2 macrophages. The aim of this study was to investigate the effects of sdLDL (small dense LDL) on the MRC1 gene expression level and secretion of histamine in the differentiated M2 macrophages from monocytes of patients with coronary artery stenosis and healthy subjects. The monocytes we...
Source: Cardiovascular and Hematological Disorders Drug Targets - January 7, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Preface.
Authors: Shen G PMID: 28049406 [PubMed - in process] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - January 6, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Articular Bleeding in Hemophilia.
Authors: Rodriguez-Merchan EC Abstract Hematologic primary prohylaxis is the gold standard of treatment in persons with hemophilia (PWH). The goal is to reduce or prevent joint bleeds and subsequent joint degeneration (hemophilic arthropathy). In acute hemarthroses, early treatment with factor (VIII or IX) replacement and rest of the joint (4 to 5 days) are paramount. In patients with inhibitors (antibodies against factor VIII or IX) we can use bypassing agents such as activated prothrombin complex concentrate (aPCC) and recombinant factor VIIa (rFVIIa). The goal is to get the rapid resolution of the joint bleed th...
Source: Cardiovascular and Hematological Disorders Drug Targets - January 6, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Should arterial embolization in recurrent spontaneous hemophilic hemarthroses refractory to intensive prophylaxis be the first invasive resort?
Authors: Rodriguez-Merchan EC Abstract This paper reviews the role of arterial embolization (AE) in recurrent spontaneous hemarthroses (RSH) that are refractory to intensive prophylaxis (RIP) in people with hemophilia (PWH). There are six articles in the literature on the topic. The total number of AEs performed so far is 78 in 69 patients. Four second AEs were required (4/78), and a third AE in one (1/78). No serious adverse effects have been reported except for a pseudoaneurym (1/78) of the femoral artery at the puncture site (that eventually required surgical repair) and for one patient (1/78) that had recurrenc...
Source: Cardiovascular and Hematological Disorders Drug Targets - January 4, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Is there any role for splenectomy in adulthood onset chronic immune thrombocytopenia in the era of TPO receptors agonists? A critical overview.
Authors: Milunovic V, Rogulj IM, Ostojic SK Abstract Immune thrombocytopenia (ITP) in adulthood is characterized by chronic relapsing course. Despite the efficacious first line treatment (corticosteroid, intravenous immunoglobulin), majority of patients will enter the chronic phase warranting another treatment approach. Until recently, splenectomy performed in ITP chronic phase represented the standard of care with long-term remissions in more than 70% of patients, but however has never been tested in clinical trials. However, with the advances of our understanding of ITP pathophysiology and the shifting focus on m...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 31, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research